Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Investment Securities (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Gains from Investment Securities readings, the most recent being $6.6 million for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 1114.63% to $6.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 134.05% increase, with the full-year FY2025 number at $5.8 million, up 11.09% from a year prior.
  • Gains from Investment Securities hit $6.6 million in Q4 2025 for Enanta Pharmaceuticals, up from -$922000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $6.6 million in Q4 2025 to a low of -$23.7 million in Q3 2024.
  • Median Gains from Investment Securities over the past 5 years was $691000.0 (2022), compared with a mean of $777000.0.
  • Biggest five-year swings in Gains from Investment Securities: surged 3827.62% in 2022 and later plummeted 753.71% in 2024.
  • Enanta Pharmaceuticals' Gains from Investment Securities stood at $97000.0 in 2021, then crashed by 94.85% to $5000.0 in 2022, then soared by 72360.0% to $3.6 million in 2023, then crashed by 84.9% to $547000.0 in 2024, then surged by 1114.63% to $6.6 million in 2025.
  • The last three reported values for Gains from Investment Securities were $6.6 million (Q4 2025), -$922000.0 (Q3 2025), and $88000.0 (Q2 2025) per Business Quant data.